BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 26929034)

  • 1. Mammalian Target of Rapamycin Inhibitor Induced Complete Remission of a Recurrent Subependymal Giant Cell Astrocytoma in a Patient Without Features of Tuberous Sclerosis Complex.
    Appalla D; Depalma A; Calderwood S
    Pediatr Blood Cancer; 2016 Jul; 63(7):1276-8. PubMed ID: 26929034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Presurgical Administration of mTOR Inhibitors in Patients with Large Subependymal Giant Cell Astrocytoma Associated with Tuberous Sclerosis Complex.
    Jiang T; Du J; Raynald ; Wang J; Li C
    World Neurosurg; 2017 Nov; 107():1053.e1-1053.e6. PubMed ID: 28866062
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EFFECTS: an expanded access program of everolimus for patients with subependymal giant cell astrocytoma associated with tuberous sclerosis complex.
    Fogarasi A; De Waele L; Bartalini G; Jozwiak S; Laforgia N; Verhelst H; Petrak B; Pedespan JM; Witt O; Castellana R; Crippa S; Gislimberti G; Gyorsok Z
    BMC Neurol; 2016 Aug; 16():126. PubMed ID: 27502586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Experience using mTOR inhibitors for subependymal giant cell astrocytoma in tuberous sclerosis complex at a single facility.
    Tomoto K; Fujimoto A; Inenaga C; Okanishi T; Imai S; Ogai M; Fukunaga A; Nakamura H; Sato K; Obana A; Masui T; Arai Y; Enoki H
    BMC Neurol; 2021 Mar; 21(1):139. PubMed ID: 33784976
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Response to everolimus in patients with giant cell astrocytoma associated to tuberous sclerosis complex].
    Mateos-González ME; López-Laso E; Vicente-Rueda J; Camino-León R; Fernández-Ramos JA; Baena-Gómez MA; Peña-Rosa MJ
    Rev Neurol; 2014 Dec; 59(11):497-502. PubMed ID: 25418144
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors affecting response to everolimus therapy for subependymal giant cell astrocytomas associated with tuberous sclerosis.
    Trelinska J; Dachowska I; Kotulska K; Baranska D; Fendler W; Jozwiak S; Mlynarski W
    Pediatr Blood Cancer; 2015 Apr; 62(4):616-21. PubMed ID: 25557360
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Retinal astrocytoma regression in tuberous sclerosis patients treated with everolimus.
    Zipori AB; Tehrani NN; Ali A
    J AAPOS; 2018 Feb; 22(1):76-79. PubMed ID: 29277498
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mammalian target of rapamycin inhibitors for intractable epilepsy and subependymal giant cell astrocytomas in tuberous sclerosis complex.
    Cardamone M; Flanagan D; Mowat D; Kennedy SE; Chopra M; Lawson JA
    J Pediatr; 2014 May; 164(5):1195-200. PubMed ID: 24518170
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose-level response rates of mTor inhibition in tuberous sclerosis complex (TSC) related subependymal giant cell astrocytoma (SEGA).
    Weidman DR; Pole JD; Bouffet E; Taylor MD; Bartels U
    Pediatr Blood Cancer; 2015 Oct; 62(10):1754-60. PubMed ID: 25929843
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of mTOR inhibitor everolimus in three neonates for treatment of tumors associated with tuberous sclerosis complex.
    Goyer I; Dahdah N; Major P
    Pediatr Neurol; 2015 Apr; 52(4):450-3. PubMed ID: 25682485
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological treatment strategies for subependymal giant cell astrocytoma (SEGA).
    Ebrahimi-Fakhari D; Franz DN
    Expert Opin Pharmacother; 2020 Aug; 21(11):1329-1336. PubMed ID: 32338549
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Everolimus tablets for patients with subependymal giant cell astrocytoma.
    Turner SG; Peters KB; Vredenburgh JJ; Desjardins A; Friedman HS; Reardon DA
    Expert Opin Pharmacother; 2011 Oct; 12(14):2265-9. PubMed ID: 21806479
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term effect of everolimus on epilepsy and growth in children under 3 years of age treated for subependymal giant cell astrocytoma associated with tuberous sclerosis complex.
    Kotulska K; Chmielewski D; Borkowska J; Jurkiewicz E; Kuczyński D; Kmieć T; Łojszczyk B; Dunin-Wąsowicz D; Jóźwiak S
    Eur J Paediatr Neurol; 2013 Sep; 17(5):479-85. PubMed ID: 23567018
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute Management of Symptomatic Subependymal Giant Cell Astrocytoma With Everolimus.
    Arroyo MS; Krueger DA; Broomall E; Stevenson CB; Franz DN
    Pediatr Neurol; 2017 Jul; 72():81-85. PubMed ID: 28511812
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Role of mTOR Inhibitors in the Treatment of Patients with Tuberous Sclerosis Complex: Evidence-based and Expert Opinions.
    Curatolo P; Bjørnvold M; Dill PE; Ferreira JC; Feucht M; Hertzberg C; Jansen A; Jóźwiak S; Kingswood JC; Kotulska K; Macaya A; Moavero R; Nabbout R; Zonnenberg BA
    Drugs; 2016 Apr; 76(5):551-65. PubMed ID: 26927950
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Natural History and Current Treatment Options for Subependymal Giant Cell Astrocytoma in Tuberous Sclerosis Complex.
    Jóźwiak S; Mandera M; Młynarski W
    Semin Pediatr Neurol; 2015 Dec; 22(4):274-81. PubMed ID: 26706014
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Everolimus: in patients with subependymal giant cell astrocytoma associated with tuberous sclerosis complex.
    Curran MP
    Paediatr Drugs; 2012 Feb; 14(1):51-60. PubMed ID: 22136276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-Term Use of Everolimus in Patients with Tuberous Sclerosis Complex: Final Results from the EXIST-1 Study.
    Franz DN; Belousova E; Sparagana S; Bebin EM; Frost MD; Kuperman R; Witt O; Kohrman MH; Flamini JR; Wu JY; Curatolo P; de Vries PJ; Berkowitz N; Niolat J; Jóźwiak S
    PLoS One; 2016; 11(6):e0158476. PubMed ID: 27351628
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Maintenance therapy with everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis (the EMINENTS study).
    Trelinska J; Dachowska I; Baranska D; Stawiski K; Kotulska K; Fendler W; Jozwiak S; Mlynarski W
    Pediatr Blood Cancer; 2017 Jun; 64(6):. PubMed ID: 27860334
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential of mTOR inhibitors for the treatment of subependymal giant cell astrocytomas in tuberous sclerosis complex.
    Major P
    Aging (Albany NY); 2011 Mar; 3(3):189-91. PubMed ID: 21415462
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.